Skip to main content
Erschienen in:

05.09.2023 | Typ-1-Diabetes in der Pädiatrie | Fortbildung

Früherkennung und Prävention von Typ-1-Diabetes

Das "window of opportunity" in den ersten 1.000 Tagen nutzen

verfasst von: Prof. Dr. Anette-Gabriele Ziegler, Prof. Dr. Sandra Hummel

Erschienen in: Pädiatrie | Sonderheft 1/2023

Einloggen, um Zugang zu erhalten

Auszug

Ob ein Kind später einmal einen Typ-1-Diabetes entwickelt, lässt sich bereits im Kindesalter über die Bestimmung von Inselautoantikörpern recht zuverlässig abschätzen. Wird ein bestehendes genetisches Risiko für Typ-1-Diabetes früh erkannt, können Kinder an Primärpräventionsstudien teilnehmen.
Literatur
1.
Zurück zum Zitat Gregory GA et al. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. Lancet Diabetes Endocrinol. 2022;10(10):741-60 Gregory GA et al. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. Lancet Diabetes Endocrinol. 2022;10(10):741-60
2.
Zurück zum Zitat Ziegler AG et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013;309(23):2473-9 Ziegler AG et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013;309(23):2473-9
3.
Zurück zum Zitat Bonifacio E et al. Maternal type 1 diabetes reduces the risk of islet autoantibodies: relationships with birthweight and maternal HbA(1c). Diabetologia. 2008;51(7):1245-52 Bonifacio E et al. Maternal type 1 diabetes reduces the risk of islet autoantibodies: relationships with birthweight and maternal HbA(1c). Diabetologia. 2008;51(7):1245-52
4.
Zurück zum Zitat Ziegler AG et al. Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes. Diabetologia. 2012;55(7):1937-43 Ziegler AG et al. Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes. Diabetologia. 2012;55(7):1937-43
5.
Zurück zum Zitat Bonifacio E et al. An age-related exponential decline in the risk of multiple islet autoantibody seroconversion during childhood. Diabetes Care. 2021;44(10):2260-8 Bonifacio E et al. An age-related exponential decline in the risk of multiple islet autoantibody seroconversion during childhood. Diabetes Care. 2021;44(10):2260-8
6.
Zurück zum Zitat Warncke K et al. Elevations in blood glucose before and after the appearance of islet autoantibodies in children. J Clin Invest. 2022;132(20):e162123 Warncke K et al. Elevations in blood glucose before and after the appearance of islet autoantibodies in children. J Clin Invest. 2022;132(20):e162123
7.
Zurück zum Zitat Insel RA et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10):1964-74 Insel RA et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10):1964-74
8.
Zurück zum Zitat Beyerlein A et al. Infections in early life and development of type 1 diabetes. JAMA. 2016;315(317):1899-901 Beyerlein A et al. Infections in early life and development of type 1 diabetes. JAMA. 2016;315(317):1899-901
9.
Zurück zum Zitat Vehik K et al. Prospective virome analyses in young children at increased genetic risk for type 1 diabetes. Nat Med. 2019;25(12):1865-72 Vehik K et al. Prospective virome analyses in young children at increased genetic risk for type 1 diabetes. Nat Med. 2019;25(12):1865-72
10.
Zurück zum Zitat Weiss A et al. Type 1 diabetes incidence and risk in children with a diagnosis of COVID-19. JAMA. 2023;329(23):2089-91 Weiss A et al. Type 1 diabetes incidence and risk in children with a diagnosis of COVID-19. JAMA. 2023;329(23):2089-91
11.
Zurück zum Zitat Beyerlein A et al. Early infant growth is associated with the risk of islet autoimmunity in genetically susceptible children. Pediatr Diabetes. 2014;15(7):534-42 Beyerlein A et al. Early infant growth is associated with the risk of islet autoimmunity in genetically susceptible children. Pediatr Diabetes. 2014;15(7):534-42
12.
Zurück zum Zitat Nucci AM et al. Growth and development of islet autoimmunity and type 1 diabetes in children genetically at risk. Diabetologia. 2021;64(4):826-35 Nucci AM et al. Growth and development of islet autoimmunity and type 1 diabetes in children genetically at risk. Diabetologia. 2021;64(4):826-35
13.
Zurück zum Zitat Ziegler AG et al. Yield of a public health screening of children for islet autoantibodies in Bavaria, Germany. JAMA. 2020;323(4):339-51 Ziegler AG et al. Yield of a public health screening of children for islet autoantibodies in Bavaria, Germany. JAMA. 2020;323(4):339-51
14.
Zurück zum Zitat Richardson TG et al. Childhood body size directly increases type 1 diabetes risk based on a lifecourse Mendelian randomization approach. Nat Commun. 2022;13(1):2337 Richardson TG et al. Childhood body size directly increases type 1 diabetes risk based on a lifecourse Mendelian randomization approach. Nat Commun. 2022;13(1):2337
15.
Zurück zum Zitat Endesfelder D et al. Towards a functional hypothesis relating anti-islet cell autoimmunity to the dietary impact on microbial communities and butyrate production. Microbiome. 2016;4:17 Endesfelder D et al. Towards a functional hypothesis relating anti-islet cell autoimmunity to the dietary impact on microbial communities and butyrate production. Microbiome. 2016;4:17
16.
Zurück zum Zitat Vatanen T et al. The human gut microbiome in early-onset type 1 diabetes from the TEDDY study. Nature. 2018;562(7728):589-94 Vatanen T et al. The human gut microbiome in early-onset type 1 diabetes from the TEDDY study. Nature. 2018;562(7728):589-94
17.
Zurück zum Zitat Uusitalo U et al. Association of early exposure of probiotics and islet autoimmunity in the teddy study. JAMA Pediatr. 2016;170(1):20-8 Uusitalo U et al. Association of early exposure of probiotics and islet autoimmunity in the teddy study. JAMA Pediatr. 2016;170(1):20-8
18.
Zurück zum Zitat Herold KC et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med. 2019;381(7):603-13 Herold KC et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med. 2019;381(7):603-13
19.
Zurück zum Zitat Forlenza GP et al. Effect of verapamil on pancreatic beta cell function in newly diagnosed pediatric type 1 diabetes: a randomized clinical trial. JAMA. 2023;329(12):990-9 Forlenza GP et al. Effect of verapamil on pancreatic beta cell function in newly diagnosed pediatric type 1 diabetes: a randomized clinical trial. JAMA. 2023;329(12):990-9
Metadaten
Titel
Früherkennung und Prävention von Typ-1-Diabetes
Das "window of opportunity" in den ersten 1.000 Tagen nutzen
verfasst von
Prof. Dr. Anette-Gabriele Ziegler
Prof. Dr. Sandra Hummel
Publikationsdatum
05.09.2023
Verlag
Springer Medizin
Erschienen in
Pädiatrie / Ausgabe Sonderheft 1/2023
Print ISSN: 1867-2132
Elektronische ISSN: 2196-6443
DOI
https://doi.org/10.1007/s15014-023-4923-x

Weitere Artikel der Sonderheft 1/2023

Pädiatrie 1/2023 Zur Ausgabe

Praxisempfehlungen der Deutschen Diabetes Gesellschaft

Kurz, prägnant und aktuell: Die Praxisempfehlungen der Deutschen Diabetes Gesellschaft.